Author

J. Chang

Observed name: J. H. Chang

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Fudan University Shanghai Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences

Observed institutions: Shanghai Medical College of Fudan University, Sun Yat-sen University, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing University of Information Science and Technology, Fudan University, Fudan University Shanghai Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences, Sun Yat-sen University Cancer Center, State Key Laboratory of Molecular Oncology

OpenAlex ID: A5111297026

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)

2017 · L. Zhang, S. Lu, et al. · Annals of Oncology · 116

PDF

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

2020 · M. Shi, A. Gu, et al. · Annals of Oncology · 76

Infrared plasmonic refractive index-sensitive nanosensor based on electromagnetically induced transparency of waveguide resonator systems

2014 · B. Ni, X. Y. Chen, et al. · Optical and Quantum Electronics · 42

653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors

2023 · J. Wang, J. Zhao, et al. · Annals of Oncology · 29

PDF

Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer

2013 · L. Huang, C. Wu, et al. · Carcinogenesis · 24

OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

2019 · C. Zhou, G. Chen, et al. · Journal of Thoracic Oncology · 23

PDF

LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

2020 · C. Zhou, Z. Wang, et al. · Annals of Oncology · 21

OA 09.06 A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC

2017 · J.-. Yang, J. Fang, et al. · Journal of Thoracic Oncology · 17

PDF

P3.01-036 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis

2017 · Y. Wu, H. Tu, et al. · Journal of Thoracic Oncology · 10

PDF

EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment

2016 · M. Nishio, T.S.K. Mok, et al. · Annals of Oncology · 10

LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)

2021 · Y-L. Wu, Q. Zhou, et al. · Annals of Oncology · 6

P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC

2021 · C. Zhou, G. Chen, et al. · Journal of Thoracic Oncology · 6

PDF

P2.01-99 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Final Analysis

2019 · Y. Wu, H. Tu, et al. · Journal of Thoracic Oncology · 5

FP14.17 Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy

2021 · Q. Zhou, Y. Wu, et al. · Journal of Thoracic Oncology · 3

PDF

P1.01-98 A Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions

2018 · Y. Wu, H. Tu, et al. · Journal of Thoracic Oncology · 3

PDF

The status of epidermal growth factor receptor (EGFR) mutations at exon 19 and 21 in Chinese patients with NSCLC

2005 · L. Zhang, X. Zhang, et al. · Journal of Clinical Oncology · 3

147P PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients

2021 · Y. Yu, L. Xia, et al. · Journal of Thoracic Oncology · 2

PDF

MA14.05 A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)

2019 · S. Lu, G. Chen, et al. · Journal of Thoracic Oncology · 2

PDF

OA10 CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

2018 · Y. Wu, J. Chang, et al. · Journal of Thoracic Oncology · 2

The effect of a 3-day oral aprepitant regimen on the prevention of CINV over standard therapy in Chinese patients receiving high-dose cisplatin.

2011 · Y. Cheng, L. Zhang, et al. · Journal of Clinical Oncology · 2

P45.08 Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

2021 · S. Lu, Q. Zhou, et al. · Journal of Thoracic Oncology · 1

PDF

1370P Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study

2023 · J. Chang, X. Wu, et al. · Annals of Oncology

PDF

592P The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer

2023 · J. Chang, W. Du, et al. · Annals of Oncology

PDF

P47.01 Plasma Exosomal Long RNA in SCLC Diagnosis and Prognosis

2021 · C. Liu, J. Wang, et al. · Journal of Thoracic Oncology

PDF

126P A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)

2020 · J. Chang, H. Wang, et al. · Annals of Oncology

PDF

Works count: 34

Citation count: 403

H-index: 10

I10-index: 10